Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/Stenting A Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association [EHRA] and the European Association of Percutaneous Cardiovascular Interventions [EAPCI]

Research output: Contribution to journalReview article

Authors

  • K Huber
  • F Andreotti
  • H Arnesen
  • KJ Airaksinen
  • T Cuisset
  • F Marin

Abstract

There remains uncertainty over optimal antithrombotic management strategy for patients with atrial fibrillation (AF) presenting with an acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Clinicians need to balance the risk of stroke and thromboembolism against the risk of recurrent cardiac ischaemia and/or stent thrombosis, and the risk of bleeding. This consensus document comprehensively reviews the published evidence and presents a consensus statement on a 'best practice' antithrombotic therapy guideline for the management of antithrombotic therapy in such AF patients.

Details

Original languageEnglish
Pages (from-to)13-28
Number of pages16
JournalThrombosis and Haemostasis
Volume103
Issue number1
Publication statusPublished - 1 Jan 2010

Keywords

  • percutaneous coronary intervention, acute coronary syndrome, warfarin, stenting, antithrombotic therapy, Arial fibrillation